1.59 0.05 (3.25%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 2.12 | 1-year : | 2.39 |
Resists | First : | 1.81 | Second : | 2.04 |
Pivot price | 1.61 ![]() |
|||
Supports | First : | 1.44 | Second : | 1.19 |
MAs | MA(5) : | 1.56 | MA(20) : | 1.65 ![]() |
MA(100) : | 3.05 ![]() |
MA(250) : | 7.9 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 15 ![]() |
D(3) : | 12.1 ![]() |
RSI | RSI(14): 44.5 ![]() |
|||
52-week | High : | 18.71 | Low : | 1.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SONN ] has closed above bottom band by 37.1%. Bollinger Bands are 87.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.6 - 1.61 | 1.61 - 1.62 |
Low: | 1.52 - 1.53 | 1.53 - 1.54 |
Close: | 1.57 - 1.59 | 1.59 - 1.61 |
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Sun, 16 Feb 2025
Sonnet BioTherapeutics appoints new chief business officer - MSN
Fri, 14 Feb 2025
Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments - TipRanks
Thu, 13 Feb 2025
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView
Thu, 13 Feb 2025
Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Thu, 13 Feb 2025
Sonnet BioTherapeutics appoints new chief business officer - Investing.com
Thu, 13 Feb 2025
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 3 (M) |
Held by Insiders | 585990 (%) |
Held by Institutions | 1.3 (%) |
Shares Short | 66 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.226e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -21 % |
Return on Assets (ttm) | 968.5 % |
Return on Equity (ttm) | -97 % |
Qtrly Rev. Growth | 55880 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -254.4 |
EBITDA (p.s.) | -6.08654e+006 |
Qtrly Earnings Growth | -11.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -10 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 0.41 |
Dividend | 0 |
Forward Dividend | 40120 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |